Prenetics

Prenetics

Biotechnology Research

Prenetics mission is to decentralize healthcare through testing covering prevention, diagnostics, and personalized care.

About us

Prenetics (NASDAQ:PRE), a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Our prevention arm, CircleDNA, uses whole exome sequencing to offer the world’s most comprehensive consumer DNA test. Insighta, our $200 million joint venture with renowned scientist Prof. Dennis Lo, underscores our unwavering commitment to saving lives through pioneering multi-cancer early detection technologies. Lastly, ACT Genomics, our treatment unit, is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Each of Prenetics’ units synergistically enhances our global impact on health, truly embodying our commitment to ‘enhancing life through science’.

Website
https://prenetics.com/
Industry
Biotechnology Research
Company size
501-1,000 employees
Headquarters
Hong Kong
Type
Public Company
Founded
2014
Specialties
DNA Testing, Personalized Medicine, Pharmacogenomics Testing, Health & Wellness, Personalised Digital Health, and oncology

Locations

  • Primary

    7/F, Prosperity Millennia Plaza, 663 King’s Road, Quarry Bay

    Hong Kong, HK

    Get directions

Employees at Prenetics

Updates

Affiliated pages

Similar pages

Funding

Prenetics 6 total rounds

Last Round

Post IPO equity

US$ 120.0M

See more info on crunchbase